Although many efforts have been made in basic research to prove how Rho proteins and downstream pathways contribute to the development of sepsis and septic shock, it is likely that the lack of system selective agents, perhaps acting as activators or inhibitors on distinct Rho proteins and downstream targets, is the key missing point, preventing this pathway from being adequately explored in the clinical management of sepsis. The gene discussed is RHO; the disease is Sepsis.